<?xml version="1.0" encoding="UTF-8"?>
<p id="Par41">A total of 11 good- and 11 non-responders were available to validate the top discovery results. Cohort characteristics were broadly similar to the discovery cohort with a minor difference in the mean baseline DAS28 (good-responders, mean = 6.27; non-responders, mean = 5.33; 
 <italic>p</italic> = 0.0005). Relative quantification was used to compare expression between baseline and 3 months of adalimumab treatment for both response groups (Fig. 
 <xref rid="Fig1" ref-type="fig">1</xref>). In good-responders differential expression was validated for 17 transcripts in the same direction of change as the initial discovery cohort (fold change &gt; 1.2, FDR 
 <italic>p</italic> &lt; 0.05; Table 
 <xref rid="Tab3" ref-type="table">3</xref>). In the equivalent analysis of non-responders, no transcripts were differentially expressed at a significant level. 
</p>
